- Conditions
- Psoriasis
- Interventions
- Med-Jet, Traditional Syringe
- Device · Other
- Lead sponsor
- University Hospitals Cleveland Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 121–144
of 147
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Macular Edema, Retinal Vein Occlusion
- Interventions
- KSI-301, Aflibercept, Sham Procedure
- Drug · Other
- Lead sponsor
- Kodiak Sciences Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 568 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 81
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Fresno, California + 75 more
- Conditions
- Heart Failure With Preserved Ejection Fraction (HFpEF
- Interventions
- Greater Splanchnic Nerve Ablation, Sham Control
- Device
- Lead sponsor
- Axon Therapies, Inc.
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2029
- U.S. locations
- 24
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 17 more
- Conditions
- Osteoarthritis of the Knee
- Interventions
- Cooled Radiofrequency, Corticosteroid injection
- Device · Drug
- Lead sponsor
- Halyard Health
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 151 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 11
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Santa Monica, California + 8 more
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Percutaneous Local Ablation, Hypofractionated Image Guided Radiation Therapy
- Procedure · Radiation
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 2
- States / cities
- Durham, North Carolina
- Conditions
- GIST
- Interventions
- EUS-TCB needle (QuickCore) standard of care, EUS-Guided biopsy needle (ProCore)
- Device
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Pancreatic Cyst
- Interventions
- 1). EUS-FNA plus MFB, 2). EUS-FNA Alone
- Procedure
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 3
- States / cities
- Irvine, California • Aurora, Colorado • Houston, Texas
- Conditions
- Scleroderma, Systemic
- Interventions
- GSK2330811, Placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Stanford, California • Chicago, Illinois + 3 more
- Conditions
- Chronic Granulomatous Diseases (CGD) and Liver Lesions
- Interventions
- Cool-tip RF Ablation System
- Device
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 75 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2020
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Benign Headache
- Interventions
- 0.5% bupivacaine, Standard Care
- Drug
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Charlotte, North Carolina
- Conditions
- 3 or More Rib Fractures
- Interventions
- ON-Q® Pain Relief System, Thoracic epidural catheter
- Procedure
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Discogenic Pain
- Interventions
- High yield pure PRP, Placebo, ProPlaz PPC
- Device · Other
- Lead sponsor
- Neurological Associates of West Los Angeles
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 7
- States / cities
- Campbell, California • Santa Monica, California • Peachtree City, Georgia + 2 more
- Conditions
- Urinary Bladder, Overactive, Incontinence, Urge, Incontinence, Urinary, Urinary Urge Incontinence, Urinary Frequency More Than Once at Night, Nocturia
- Interventions
- OnabotulinumtoxinA 100 UNT
- Drug
- Lead sponsor
- University of South Florida
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia • Tampa, Florida
- Conditions
- Vitiligo
- Interventions
- Needling, Triamcinolone
- Procedure · Drug
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Somerset, New Jersey
- Conditions
- Gestatiaonl Diabetes Mellitus, Pregnancy, Diabetes in Pregnancy, Insulin Dependent Diabetes Mellitus, Insulin
- Interventions
- Injection Port for Insulin Administration, Single-Use Insulin Needles
- Device
- Lead sponsor
- University of Texas at Austin
- Other
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Urgent Urinary Incontinence
- Interventions
- selective bladder denervation using RF energy
- Device
- Lead sponsor
- Hologic, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 225 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2030
- U.S. locations
- 6
- States / cities
- Wichita, Kansas • Shreveport, Louisiana • Pittsburgh, Pennsylvania + 2 more
- Conditions
- Sacroiliac Joint Somatic Dysfunction
- Interventions
- CornerLoc SI Joint Stabilization Procedure, Intra-articular Sacroiliac Joint Steroid Injection
- Device · Drug
- Lead sponsor
- CornerLoc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Lancaster, Pennsylvania
- Conditions
- Prostate Cancer
- Interventions
- Focal Laser Ablation
- Procedure
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 40 Years to 85 Years · Male only
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Diabetes, Healthcare Professionals, Delivery Systems
- Interventions
- safety glide, autocover needle
- Device
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 83 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2006
- U.S. locations
- 1
- States / cities
- Plainsboro, New Jersey
- Conditions
- Anxiety Disorder, Breast Cancer, Depression, Fatigue, Hot Flashes, Pain, Sleep Disorders
- Interventions
- acupuncture therapy, sham intervention
- Procedure
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland
- Conditions
- Diabetic Foot, Venous Ulcer, Pressure Ulcer
- Interventions
- Adipose derived stem cells
- Drug
- Lead sponsor
- Tower Outpatient Surgical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Quantity of Tissue Obtained, Quality of Tissue Obtained, Ease of Use of 22-gauge ProCore EBUS Needles and the Standard 22-gauge Needles
- Interventions
- 22-gauge Standard Needle, 22-gauge ProCore Needle
- Other
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 4
- States / cities
- Gainesville, Florida • Baltimore, Maryland • Chapel Hill, North Carolina + 1 more
- Conditions
- Plaque Psoriasis.
- Interventions
- Gadolinium, Efficacy of Enbrel subcutaneously at Week 12, Efficacy of Enbrel subcutaneously at Week 24, Efficacy of Enbrel subcutaneously at Week 36, Efficacy of Enbrel subdermally at Week 12, Efficacy of Enbrel subdermally at Week 24, Efficacy of Enbrel subdermally at Week 36, PASI 75 n(%) subcutaneously at Week 12, PASI 75 n(%) subcutaneously at Week 24, PASI 75 n(%) subcutaneously at Week 36, PASI 75 n(%) subdermally at Week 12, PASI 75 n(%) subdermally at Week 24, PASI 75 n(%) subdermally at Week 36, Adverse Reactions of Enbrel subcutaneously, Adverse Reactions of Enbrel subdermally at Week 36
- Drug
- Lead sponsor
- ASIS Corporation
- Industry
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Westminster, California
- Conditions
- Healthy
- Interventions
- Autologous apheresis Platelet Components, prepared with the INTERCEPT Blood System for Platelets., Autologous apheresis Conventional untreated Platelet Components
- Biological
- Lead sponsor
- Cerus Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 2
- States / cities
- Lebanon, New Hampshire • Cincinnati, Ohio